Abstract: Endometriosis is a chronic inflammatory systemic sex hormone-dependent gynecological disease, characterized by the presence and growth of endometrial tissue (glands and stroma) outside the uterine cavity, predominantly, but not exclusively, in the pelvic compartment. Here, the inventors show that the use of Neuropilin/VEGF binding inhibitors, so called, Neuropilin antagonist (NRPa), bring new perspective to treat and cure endometriosis in women suffering thereof. NRPa alone is efficient to inhibit primary endometrial cell proliferation and apoptosis/necrosis program cell death of targeted cells. The effective NRPa concentration needed is very low (NRPa-48 IC50=10?7M) and is dependent of the NRPa structure. Moreover, the association of NRPa with progestogen drug increases the anti-proliferative effect. Therefore, the present invention relates to the use of neuropilin antagonists for the treatment of endometriosis.

Abstract: The invention relates to the use of a radiofrequency/microwave treatment device and its effect on cell growth and survival, and in a more particular embodiment on endometriotic cells. In another aspect, the invention relates to the use of radiofrequency/microwave energy to effect cell growth in a desired population while substantially avoiding the deleterious heating and destructive effects on neighboring or nearby cells. Using the devices, specific treatment regimens and controlling energy output to cells and tissue can effect specific cells and diseases of humans, for example, those involving uncontrolled or deleterious cell growth.